case_images: PMC4698324_01
case_images: Chest X-ray examination and T1-weighted magnetic resonance imaging (MRI) with gadolinium. a
  Chest X-ray examination shows consolidation of the lung and pleural fluid. b and c Axial and coronal T1-weighted MRI with gadolinium. An enhanced mass lesion (red arrows) in the left temporal lobe was observed on admission. d The consolidation of the lung and pleural fluid was not detected 1 month after the administration of gefitinib. e and f Brain metastasis was not detected 1 month after the administration of gefitinib
case_images: 13104_2015_1834_Fig1_HTML.jpg
case_images: PMC4698324_01_13104_2015_1834_Fig1_HTML.jpg
case_images: Fig1
case_images: A 70-year-old Japanese woman without a history of smoking presented at our hospital with a persistent cough, respiratory discomfort, and a chest X-ray abnormality (Fig. 1a). Sequential brain magnetic resonance imaging (MRI) revealed an enhancing nodule in the left temporal lobe (Fig. 1b, c). One month after the initiation of gefitinib, both the primary lesion and metastatic lesion were indiscernible on a follow-up chest X-ray and brain MRI (Fig. 1d, e, f).
case_images: PMC4698324_02
case_images: Chest X-ray examination and coronal T1-weighted magnetic resonance imaging with gadolinium. a
  Chest X-ray examination shows consolidation of the right lung. b Enhanced mass lesion (red arrow) and meningeal dissemination were revealed on admission. c The consolidation of the right lung was not detected 3 weeks after the administration of gefitinib. d Neither brain metastasis nor meningeal dissemination was detected 3 weeks after the administration of gefitinib
case_images: 13104_2015_1834_Fig2_HTML.jpg
case_images: PMC4698324_02_13104_2015_1834_Fig2_HTML.jpg
case_images: Fig2
case_images: A 58-year-old Japanese woman without a history of smoking presented at our hospital with nausea, headache, and a chest X-ray abnormality (Fig. 2a). Sequential brain MRI showed an enhancing nodule in the left cerebellar hemisphere and meningeal dissemination (Fig. 2b). Three weeks after the initiation of gefitinib, both the primary and metastatic lesions were indiscernible on a follow-up chest X-ray and brain MRI (Fig. 2c, d).